نتایج جستجو برای: kinase inhibitors

تعداد نتایج: 385681  

2012
Alexis Bretteville François Marcouiller Carl Julien Noura B. El Khoury Franck R. Petry Isabelle Poitras Didier Mouginot Georges Lévesque Sébastien S. Hébert Emmanuel Planel

Tau hyperphosphorylation is one hallmark of Alzheimer's disease (AD) pathology. Pharmaceutical companies have thus developed kinase inhibitors aiming to reduce tau hyperphosphorylation. One obstacle in screening for tau kinase inhibitors is the low phosphorylation levels of AD-related phospho-epitopes in normal adult mice and cultured cells. We have shown that hypothermia induces tau hyperphosp...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2007
Ultan McDermott Sreenath V Sharma Lori Dowell Patricia Greninger Clara Montagut Jennifer Lamb Heidi Archibald Raul Raudales Angela Tam Diana Lee S Michael Rothenberg Jeffrey G Supko Raffaella Sordella Lindsey E Ulkus A John Iafrate Shyamala Maheswaran Ching Ni Njauw Hensin Tsao Lisa Drew Jeff H Hanke Xiao-Jun Ma Mark G Erlander Nathanael S Gray Daniel A Haber Jeffrey Settleman

Kinase inhibitors constitute an important new class of cancer drugs, whose selective efficacy is largely determined by underlying tumor cell genetics. We established a high-throughput platform to profile 500 cell lines derived from diverse epithelial cancers for sensitivity to 14 kinase inhibitors. Most inhibitors were ineffective against unselected cell lines but exhibited dramatic cell killin...

2011
Roberta Bitencourt Ilana Zalcberg Iúri Drumond Louro

The development of point mutations in the BCR-ABL kinase domain is the main reason for imatinib resistance in chronic myeloid leukemia. Different detection methods are used in chronic myeloid leukemia monitoring, such as direct sequencing, denaturing high performance liquid chromatography and allele specific polymerase chain reaction. Mutation analysis has become mandatory during patient workup...

Journal: :British journal of pharmacology 2015
Doriano Fabbro Sandra W Cowan-Jacob Henrik Moebitz

Many human malignancies are associated with aberrant regulation of protein or lipid kinases due to mutations, chromosomal rearrangements and/or gene amplification. Protein and lipid kinases represent an important target class for treating human disorders. This review focus on 'the 10 things you should know about protein kinases and their inhibitors', including a short introduction on the histor...

Journal: :journal of sciences, islamic republic of iran 2015
t. akbarzadeh a. rafinejad a. fallah-tafti r. tiwari a. nasrolahi shirazi

in this work, different ethyl 2,4-dioxo-4-arylbutanoate derivatives were prepared and evaluated for their src kinase inhibitory activity. for this purpose, the appropriate substituted acetophenone derivatives reacted with diethyl oxalate in the presence of sodium ethoxide in dried ethanol to give the corresponding products. all compounds showed moderate activities comparing with staurosporine a...

Journal: :Cell chemical biology 2016
Saadat Aleem George Georghiou Ralph E Kleiner Kip Guja Barbara P Craddock Agatha Lyczek Alix I Chan Miguel Garcia-Diaz W Todd Miller David R Liu Markus A Seeliger

Protein kinases are attractive therapeutic targets because their dysregulation underlies many diseases, including cancer. The high conservation of the kinase domain and the evolution of drug resistance, however, pose major challenges to the development of specific kinase inhibitors. We recently discovered selective Src kinase inhibitors from a DNA-templated macrocycle library. Here, we reveal t...

Journal: :Translational lung cancer research 2023

Background: Patients with non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) fusions may benefit from ALK-tyrosine inhibitors (ALK-TKIs). However, few studies have analyzed the clinical outcome in patients multiple ALK fusions, including double or triple fusions. Here, our study aimed to analyze impact of on efficacy receiving ALK-TKIs NSCLC patients.

2017
Zheng Zhao Lei Xie Philip E Bourne

Protein kinases are critical drug targets for treating a large variety of human diseases. Type-III kinase inhibitors have attracted increasing attention as highly selective therapeutics. Thus, understanding the binding mechanism of existing type-III kinase inhibitors provides useful insights into designing new type-III kinase inhibitors. In this work, we have systematically studied the binding ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید